1138087-95-2Relevant academic research and scientific papers
Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors
Jones, Kristen L.G.,Holloway, M. Katharine,Su, Hua-Poo,Carroll, Steven S.,Burlein, Christine,Touch, Sinoeun,DiStefano, Daniel J.,Sanchez, Rosa I.,Williams, Theresa M.,Vacca, Joseph P.,Coburn, Craig A.
scheme or table, p. 4065 - 4068 (2010/09/04)
A series of HIV-1 protease inhibitors containing an epsilon substituted lysinol backbone was synthesized. Two novel synthetic routes using N-boc-l-glutamic acid alpha-benzyl ester and 2,6-diaminopimelic acid were developed. Incorporation of this epsilon s
HIV PROTEASE INHIBITORS
-
Page/Page column 168-169, (2009/05/29)
Compounds of Formula I are disclosed: (I), wherein XA, k, R1, R2, R3, R4, R5, R5A, R6, R6A, R7 and R8 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
